There is a considerable delay from prescription of biologic therapy to final approval for pediatric patients, and almost 40% of prescriptions requiring a prior authorization (PA) are denied, according to a study presented at the annual meeting of the American College of Allergy, Asthma and Immunology, held from Nov. 12 to 16 in Phoenix.
❓ Unknown
ACAAI: Considerable delay seen from Rx to approval for children's biologics
Just now
November 17, 2026
1 min read
📰 Medical Xpress
📋 Key Takeaway
This article discusses delays in biologic therapy approval for pediatric patients in the United States, with nearly 40% of prescriptions being denied during prior authorization. This is not related to Iran and has no direct relevance to Iranian affairs.
🏷️ Entities Mentioned
🌐
Translated from the original and edited for English readers. View original source →
Translation confidence: 100%
📰 Related Coverage
Just now •
Davoud Rokhbin Executed for Murder in Kashan Prison
Just now •
Ali Mokhtari Executed for Rape in Shahre Kord
Just now •
US Army major who survived Iran's Port Shuaiba drone strike criticizes Pentagon's troop protection failures
Just now •
Iran's Parliament Speaker Accuses US of Campaign to Reverse American Opposition to Military Action Against…
16 min ago •